Cantor Fitzgerald Reaffirms Buy Rating for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating restated by investment analysts at Cantor Fitzgerald in a research report issued on Sunday. They currently have a $200.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 43.92% from the stock’s current price.

Other research analysts have also issued reports about the stock. FBR & Co initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $206.00 price target for the company. Royal Bank Of Canada reduced their price target on shares of Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating for the company in a research report on Wednesday, November 8th. Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 28th. They set a “neutral” rating and a $165.00 price target for the company. UBS restated a “buy” rating and set a $172.00 price target (down from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th. Finally, Stifel Nicolaus restated a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 30th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $181.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded up $4.14 during trading on Friday, reaching $138.97. 544,900 shares of the company were exchanged, compared to its average volume of 507,108. Jazz Pharmaceuticals has a fifty-two week low of $101.37 and a fifty-two week high of $163.75. The stock has a market cap of $8,331.32, a price-to-earnings ratio of 17.44, a price-to-earnings-growth ratio of 0.90 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Patrick G. Enright sold 352 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $133.19, for a total transaction of $46,882.88. Following the completion of the transaction, the director now owns 1,365 shares in the company, valued at approximately $181,804.35. The disclosure for this sale can be found here. Insiders sold 10,352 shares of company stock valued at $1,417,763 over the last three months. 4.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Toronto Dominion Bank increased its position in shares of Jazz Pharmaceuticals by 12.4% during the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the period. US Bancorp DE increased its position in shares of Jazz Pharmaceuticals by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the period. Gargoyle Investment Advisor L.L.C. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at about $206,000. Advisor Group Inc. increased its position in shares of Jazz Pharmaceuticals by 62.4% during the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after buying an additional 550 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at about $211,000. Institutional investors own 91.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://sportsperspectives.com/2017/12/11/cantor-fitzgerald-reaffirms-buy-rating-for-jazz-pharmaceuticals-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply